RU2721401C2 - Способы лечения или облегчения мигрени - Google Patents

Способы лечения или облегчения мигрени Download PDF

Info

Publication number
RU2721401C2
RU2721401C2 RU2017101410A RU2017101410A RU2721401C2 RU 2721401 C2 RU2721401 C2 RU 2721401C2 RU 2017101410 A RU2017101410 A RU 2017101410A RU 2017101410 A RU2017101410 A RU 2017101410A RU 2721401 C2 RU2721401 C2 RU 2721401C2
Authority
RU
Russia
Prior art keywords
migraine
patient
once
compound
glyx
Prior art date
Application number
RU2017101410A
Other languages
English (en)
Russian (ru)
Other versions
RU2017101410A3 (enExample
RU2017101410A (ru
Inventor
Джозеф Р. МОСКАЛ
Патрик СТЭНТОН
Original Assignee
Нортвестерн Юниверсити
Наурекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нортвестерн Юниверсити, Наурекс, Инк. filed Critical Нортвестерн Юниверсити
Publication of RU2017101410A publication Critical patent/RU2017101410A/ru
Publication of RU2017101410A3 publication Critical patent/RU2017101410A3/ru
Application granted granted Critical
Publication of RU2721401C2 publication Critical patent/RU2721401C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2017101410A 2014-06-23 2015-06-23 Способы лечения или облегчения мигрени RU2721401C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462015727P 2014-06-23 2014-06-23
US62/015,727 2014-06-23
US201562109386P 2015-01-29 2015-01-29
US62/109,386 2015-01-29
PCT/US2015/037177 WO2015200322A1 (en) 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine

Publications (3)

Publication Number Publication Date
RU2017101410A RU2017101410A (ru) 2018-07-24
RU2017101410A3 RU2017101410A3 (enExample) 2019-01-21
RU2721401C2 true RU2721401C2 (ru) 2020-05-19

Family

ID=54938737

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017101410A RU2721401C2 (ru) 2014-06-23 2015-06-23 Способы лечения или облегчения мигрени

Country Status (10)

Country Link
EP (1) EP3157943A4 (enExample)
JP (2) JP6688748B2 (enExample)
KR (1) KR20170018072A (enExample)
CN (1) CN106661085A (enExample)
AU (1) AU2015280108B2 (enExample)
BR (1) BR112016030375A8 (enExample)
CA (1) CA2953170A1 (enExample)
MX (1) MX2016017388A (enExample)
RU (1) RU2721401C2 (enExample)
WO (1) WO2015200322A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2781099C1 (ru) * 2021-10-13 2022-10-05 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ лечения эпизодической мигрени

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210151836A (ko) * 2019-04-15 2021-12-14 페린 파마슈티칼즈, 인코포레이티드 편두통의 치료

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053835A1 (en) * 2000-11-17 2004-03-18 Sophia Kossida Regulation of human nmda receptor
US20120295852A1 (en) * 2009-10-05 2012-11-22 Joseph Moskal Methods of treating depression and other related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006468A1 (en) * 1993-09-01 1995-03-09 Smithkline Beecham Corporation Method for treating migraine headaches
US6884910B2 (en) * 2000-08-25 2005-04-26 Research Corporation Technologies, Inc. Uses for amino acid anticonvulsants
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
AU2009274876C1 (en) * 2008-07-23 2016-08-18 Kyowa Kirin Co., Ltd. Therapeutic agent for migraine
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
PT2485751E (pt) * 2009-10-05 2014-09-01 Univ Northwestern Glyx-13 para uso num método para tratar depressão refratária
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
AU2013329000A1 (en) * 2012-10-12 2015-04-30 Northwestern University Methods of identifying compounds for treating depression and other related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053835A1 (en) * 2000-11-17 2004-03-18 Sophia Kossida Regulation of human nmda receptor
US20120295852A1 (en) * 2009-10-05 2012-11-22 Joseph Moskal Methods of treating depression and other related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG M. et al. "Effects of NMDA receptor antagonists with different subtype selectivities on retinal spreading depression". British J Pharmacol 2012;165:235-244. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2781099C1 (ru) * 2021-10-13 2022-10-05 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ лечения эпизодической мигрени

Also Published As

Publication number Publication date
JP2020114863A (ja) 2020-07-30
CN106661085A (zh) 2017-05-10
AU2015280108B2 (en) 2019-11-28
MX2016017388A (es) 2018-02-19
EP3157943A1 (en) 2017-04-26
RU2017101410A3 (enExample) 2019-01-21
BR112016030375A2 (pt) 2017-08-15
JP2017519778A (ja) 2017-07-20
JP6688748B2 (ja) 2020-04-28
AU2015280108A1 (en) 2017-01-19
CA2953170A1 (en) 2015-12-30
BR112016030375A8 (pt) 2021-07-13
WO2015200322A1 (en) 2015-12-30
RU2017101410A (ru) 2018-07-24
KR20170018072A (ko) 2017-02-15
EP3157943A4 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
Li et al. Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition
ES2791764T3 (es) Composiciones de buprenorfina y antagonistas del receptor de opioides mu
JP6574769B2 (ja) 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
US20090163451A1 (en) Methods for treating visceral pain
US20190022225A1 (en) Protocol for increasing life expectancy in a test subject
US12144815B2 (en) Use of aprepitant for treating Alzheimer's disease
JP2022504181A (ja) 強皮症の治療のための方法
US11419857B2 (en) Methods and compositions for treating pain
RU2721401C2 (ru) Способы лечения или облегчения мигрени
WO2022271362A1 (en) Composition and methods for treating dry eye
WO2019157085A2 (en) INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS
JP6031722B2 (ja) 女性の排尿障害の治療剤
Saad et al. Nitric oxide of the supraoptic nucleus influences the salivary secretion, sodium renal excretion, urinary volume and arterial blood pressure induced by pilocarpine
JP2018502094A (ja) 親油性薬剤を歯髄に送達するため、および象牙質生成を増強するための組成物および方法
Andreou Involvement of kainate glutamate receptors in the modulation of neuronal transmission in brain areas involved in migraine pathophysiology
Goodfellow Altered NMDA Receptor Composition and Function Contribute to Deficits in Forebrain-Dependent Learning and Memory in Adult Rats Exposed to Ethanol as Neonates
Arroja Cerebral damage following ischaemic stroke: the role of Angiotensin-(1-7)